UK markets closed

Innate Pharma S.A. (IPHYF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
5.900.00 (0.00%)
At close: 11:59AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.90
Open5.90
BidN/A x N/A
AskN/A x N/A
Day's range5.90 - 5.90
52-week range3.15 - 11.00
Volume967
Avg. volume2,201
Market cap468.596M
Beta (5Y monthly)-0.14
PE ratio (TTM)N/A
EPS (TTM)-1.14
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Number of Shares and Voting Rights of Innate Pharma as of October 1, 2021

    MARSEILLE, France, October 15, 2021--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris:– IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at October 1, 2021:

  • Globe Newswire

    Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

    MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784

  • Motley Fool

    Here's Why Innate Pharma Stock Is Rocketing Higher Today

    Shares of Innate Pharma (NASDAQ: IPHA), a clinical-stage biotechnology company, are rocketing higher in response to successful clinical-trial data for an experimental cancer drug called monalizumab. Monalizumab is currently in a phase 2 trial called Coast, in combination with Imfinzi from AstraZeneca (NASDAQ: AZN). Imfinzi is approved to treat advanced-stage non-small cell lung cancer (NSCLC) patients with tumors that haven't grown since beginning standard first-line treatment.